JP2018134084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018134084A5 JP2018134084A5 JP2018071318A JP2018071318A JP2018134084A5 JP 2018134084 A5 JP2018134084 A5 JP 2018134084A5 JP 2018071318 A JP2018071318 A JP 2018071318A JP 2018071318 A JP2018071318 A JP 2018071318A JP 2018134084 A5 JP2018134084 A5 JP 2018134084A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disease
- injury
- isolated polypeptide
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000014674 injury Diseases 0.000 claims 47
- 229920001184 polypeptide Polymers 0.000 claims 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 230000006378 damage Effects 0.000 claims 24
- 230000008736 traumatic injury Effects 0.000 claims 22
- 208000027418 Wounds and injury Diseases 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 208000001647 Renal Insufficiency Diseases 0.000 claims 14
- 201000006370 kidney failure Diseases 0.000 claims 14
- 210000004556 brain Anatomy 0.000 claims 10
- 206010021143 Hypoxia Diseases 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 206010003497 Asphyxia Diseases 0.000 claims 6
- 208000027534 Emotional disease Diseases 0.000 claims 6
- 208000010412 Glaucoma Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 206010015037 epilepsy Diseases 0.000 claims 6
- 208000028867 ischemia Diseases 0.000 claims 6
- 210000001428 peripheral nervous system Anatomy 0.000 claims 6
- 210000000278 spinal cord Anatomy 0.000 claims 6
- 230000008733 trauma Effects 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 230000007954 hypoxia Effects 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000010496 Heart Arrest Diseases 0.000 claims 4
- 208000032843 Hemorrhage Diseases 0.000 claims 4
- 201000009906 Meningitis Diseases 0.000 claims 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 4
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 208000034158 bleeding Diseases 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 206010014599 encephalitis Diseases 0.000 claims 4
- 230000004968 inflammatory condition Effects 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 210000001525 retina Anatomy 0.000 claims 4
- 208000009174 transverse myelitis Diseases 0.000 claims 4
- 208000028389 Nerve injury Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000008764 nerve damage Effects 0.000 claims 3
- 230000002669 organ and tissue protective effect Effects 0.000 claims 3
- 230000000472 traumatic effect Effects 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 206010002199 Anaphylactic shock Diseases 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 208000001408 Carbon monoxide poisoning Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010063094 Cerebral malaria Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010010254 Concussion Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims 2
- 201000006306 Cor pulmonale Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 206010013647 Drowning Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 208000022555 Genital disease Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000013016 Hypoglycemia Diseases 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000009773 Insulin Coma Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000029578 Muscle disease Diseases 0.000 claims 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 2
- 206010051606 Necrotising colitis Diseases 0.000 claims 2
- 206010028885 Necrotising fasciitis Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 206010031252 Osteomyelitis Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 claims 2
- 208000008601 Polycythemia Diseases 0.000 claims 2
- 208000024777 Prion disease Diseases 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 claims 2
- 208000025747 Rheumatic disease Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010040576 Shock hypoglycaemic Diseases 0.000 claims 2
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims 2
- 208000010513 Stupor Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 208000000491 Tendinopathy Diseases 0.000 claims 2
- 206010043255 Tendonitis Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 2
- 208000012931 Urologic disease Diseases 0.000 claims 2
- 206010053648 Vascular occlusion Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 208000018839 Wilson disease Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 208000013968 amyotrophic lateral sclerosis-parkinsonism-dementia complex Diseases 0.000 claims 2
- 208000014450 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 Diseases 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 230000003276 anti-hypertensive effect Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 206010008129 cerebral palsy Diseases 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 230000009514 concussion Effects 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000024732 dysthymic disease Diseases 0.000 claims 2
- 208000002296 eclampsia Diseases 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 208000013643 idiopathic inflammatory myopathy Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 230000006371 metabolic abnormality Effects 0.000 claims 2
- 210000002161 motor neuron Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 2
- 201000007970 necrotizing fasciitis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 210000001328 optic nerve Anatomy 0.000 claims 2
- 208000024691 pancreas disease Diseases 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 2
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 230000000506 psychotropic effect Effects 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000032253 retinal ischemia Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000033764 rhythmic process Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- 210000003497 sciatic nerve Anatomy 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 201000002859 sleep apnea Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 201000004415 tendinitis Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims 2
- 208000014001 urinary system disease Diseases 0.000 claims 2
- 208000021331 vascular occlusion disease Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000007971 neurological deficit Effects 0.000 claims 1
- 230000004693 neuron damage Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70574105P | 2005-08-05 | 2005-08-05 | |
| US60/705,741 | 2005-08-05 | ||
| US70627605P | 2005-08-08 | 2005-08-08 | |
| US60/706,276 | 2005-08-08 | ||
| US83173706P | 2006-07-18 | 2006-07-18 | |
| US60/831,737 | 2006-07-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016114010A Division JP6491621B2 (ja) | 2005-08-05 | 2016-06-08 | 組織保護ペプチド及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020013151A Division JP2020078317A (ja) | 2005-08-05 | 2020-01-30 | 組織保護ペプチド及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018134084A JP2018134084A (ja) | 2018-08-30 |
| JP2018134084A5 true JP2018134084A5 (enExample) | 2018-11-08 |
Family
ID=37728020
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525285A Expired - Fee Related JP5274253B2 (ja) | 2005-08-05 | 2006-08-07 | 組織保護ペプチド及びその使用 |
| JP2013027479A Expired - Fee Related JP5918155B2 (ja) | 2005-08-05 | 2013-02-15 | 組織保護ペプチド及びその使用 |
| JP2015020020A Expired - Fee Related JP6158235B2 (ja) | 2005-08-05 | 2015-02-04 | 組織保護ペプチド及びその使用 |
| JP2016114010A Expired - Fee Related JP6491621B2 (ja) | 2005-08-05 | 2016-06-08 | 組織保護ペプチド及びその使用 |
| JP2018071318A Pending JP2018134084A (ja) | 2005-08-05 | 2018-04-03 | 組織保護ペプチド及びその使用 |
| JP2020013151A Pending JP2020078317A (ja) | 2005-08-05 | 2020-01-30 | 組織保護ペプチド及びその使用 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525285A Expired - Fee Related JP5274253B2 (ja) | 2005-08-05 | 2006-08-07 | 組織保護ペプチド及びその使用 |
| JP2013027479A Expired - Fee Related JP5918155B2 (ja) | 2005-08-05 | 2013-02-15 | 組織保護ペプチド及びその使用 |
| JP2015020020A Expired - Fee Related JP6158235B2 (ja) | 2005-08-05 | 2015-02-04 | 組織保護ペプチド及びその使用 |
| JP2016114010A Expired - Fee Related JP6491621B2 (ja) | 2005-08-05 | 2016-06-08 | 組織保護ペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020013151A Pending JP2020078317A (ja) | 2005-08-05 | 2020-01-30 | 組織保護ペプチド及びその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US8071554B2 (enExample) |
| EP (5) | EP2540309B1 (enExample) |
| JP (6) | JP5274253B2 (enExample) |
| KR (7) | KR20180067735A (enExample) |
| CN (2) | CN101378772B (enExample) |
| AU (1) | AU2006278264B2 (enExample) |
| BR (1) | BRPI0614529A8 (enExample) |
| CA (3) | CA2982909A1 (enExample) |
| DK (3) | DK2594279T3 (enExample) |
| EA (1) | EA015672B1 (enExample) |
| ES (3) | ES2653790T3 (enExample) |
| HU (3) | HUE035793T2 (enExample) |
| IL (3) | IL189287A (enExample) |
| IN (1) | IN2014CN02050A (enExample) |
| LT (2) | LT2540309T (enExample) |
| MX (3) | MX364100B (enExample) |
| NO (1) | NO20081112L (enExample) |
| NZ (1) | NZ565937A (enExample) |
| PL (3) | PL2540309T3 (enExample) |
| PT (3) | PT2371855E (enExample) |
| SG (2) | SG10201805825SA (enExample) |
| SI (3) | SI2594279T1 (enExample) |
| UA (1) | UA100222C2 (enExample) |
| WO (1) | WO2007019545A2 (enExample) |
| ZA (1) | ZA201101890B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| US9585932B2 (en) * | 2005-04-29 | 2017-03-07 | Peter C. Dowling | Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders |
| US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| PT2371855E (pt) | 2005-08-05 | 2015-11-03 | Araim Pharmaceuticals Inc | Péptidos protetores de tecidos e suas utilizações |
| CA2654154A1 (en) * | 2006-06-07 | 2007-12-13 | The University Of Tokushima | Treatment of ischemic diseases using erythropoietin |
| DK2081956T3 (da) * | 2006-11-13 | 2013-06-24 | Charite Universitaetsmedizin | FREMGANGSMÅDE TIL CELLEDYRKNING OG FREMGANGSMÅDE TIL BEHANDLING OMFATTENDE EN vEPO-PROTEINVARIANT |
| AU2016203452B2 (en) * | 2008-01-22 | 2018-02-22 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| AU2014203195B2 (en) * | 2008-01-22 | 2016-03-31 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| SG10201604530SA (en) * | 2008-01-22 | 2016-07-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| US8791234B2 (en) * | 2010-10-14 | 2014-07-29 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
| US9566349B2 (en) * | 2010-10-14 | 2017-02-14 | Rutgers, The State University Of New Jersey | Intestinal peptide targeting ligands |
| CN102180948A (zh) * | 2011-03-03 | 2011-09-14 | 复旦大学附属中山医院 | 一种具有肾脏保护作用的短肽及其制备方法和应用 |
| CN102212111B (zh) * | 2011-05-05 | 2014-04-30 | 中国人民解放军第三军医大学 | 小分子多肽和小分子多肽脂质体及其运用 |
| CA2843014C (en) * | 2011-07-27 | 2020-01-21 | Neumedicines, Inc. | Use of il-12 to generate endogenous erythropoietin |
| US20140249573A1 (en) * | 2011-09-20 | 2014-09-04 | A.A. Cash Technology Ltd. | Methods and devices for occluding blood flow to an organ |
| KR101148191B1 (ko) * | 2011-09-27 | 2012-05-23 | 김후정 | 에리스로포이에틴-유래 펩타이드 및 그 용도 |
| WO2013158871A1 (en) | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of erythropoietin and derivatives for treating hypertension |
| KR20160052537A (ko) * | 2013-07-17 | 2016-05-12 | 아라임 파마슈티칼즈, 인크. | 조직 손상과 연관된 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체 |
| CN104744593A (zh) * | 2013-12-25 | 2015-07-01 | 深圳先进技术研究院 | 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用 |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| KR20150130616A (ko) * | 2014-05-13 | 2015-11-24 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
| CN105837662A (zh) * | 2014-06-22 | 2016-08-10 | 马恒标 | 组织保护活性多肽sl3及其应用 |
| MX391259B (es) | 2015-10-14 | 2025-03-21 | X Therma Inc | Composiciones y métodos para reducir la formación de cristales de hielo. |
| JP2019523633A (ja) | 2016-04-29 | 2019-08-29 | アライム ファーマシューティカルズ，インコーポレーテッド | 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド |
| US10456346B2 (en) | 2016-11-10 | 2019-10-29 | Asc Regenity Ltd. | Cosmetic formulations for topical applications containing erythropoietin-derived molecules |
| KR101965814B1 (ko) | 2017-02-27 | 2019-08-13 | 재단법인 대구경북과학기술원 | 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용 |
| US11260101B2 (en) | 2017-02-28 | 2022-03-01 | Jinan University | Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof |
| CN108503690B (zh) * | 2017-02-28 | 2020-07-03 | 暨南大学 | 一种促进创伤后组织修复与再生的修复肽及其应用 |
| EP3761959A4 (en) * | 2018-04-08 | 2022-03-02 | Brim Biotechnology, Inc. | APPLICATION OF PEDF DERIVED SHORT PEPTIDES IN TENDON HEALING |
| KR102300060B1 (ko) | 2018-06-12 | 2021-09-08 | 주식회사 엘지에너지솔루션 | 2열 터미널 구조의 pcb 다이렉트 커넥터 |
| CN120267815A (zh) | 2018-09-10 | 2025-07-08 | 冷泉港实验室 | 用于治疗胰腺炎的方法 |
| CN112390877B (zh) * | 2019-08-16 | 2022-10-04 | 董红燕 | Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用 |
| CN118255845B (zh) * | 2022-12-27 | 2025-07-11 | 上海瑞吉康生物医药有限公司 | 相分离逆转多肽的变体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| US4558006A (en) | 1983-02-04 | 1985-12-10 | Kirin-Amgen, Inc. | A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| US4798824A (en) | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US5498694A (en) | 1989-05-25 | 1996-03-12 | La Jolla Cancer Research Foundation | Peptides of the cytoplasmic domain of integrin |
| DE3924746A1 (de) | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
| WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US6140120A (en) * | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
| US5559103A (en) | 1993-07-21 | 1996-09-24 | Cytel Corporation | Bivalent sialyl X saccharides |
| US5700909A (en) | 1993-07-30 | 1997-12-23 | The Regents Of The University Of California | Prosaposin and cytokine-derived peptides |
| US5571787A (en) | 1993-07-30 | 1996-11-05 | Myelos Corporation | Prosaposin as a neurotrophic factor |
| WO1995021919A2 (en) * | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Protein having tpo activity |
| ITFI940106A1 (it) * | 1994-05-27 | 1995-11-27 | Menarini Ricerche Sud Spa | Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica |
| US5576423A (en) | 1994-12-02 | 1996-11-19 | Schering Corporation | Antibodies to the slam protein expressed on activated T cells |
| EP0886648B8 (en) * | 1995-06-07 | 2004-03-03 | Ortho Pharmaceutical Corporation | Compounds and peptides that bind to the erythropoietin receptor |
| JP2001524944A (ja) * | 1997-03-05 | 2001-12-04 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 神経障害性疼痛の緩和方法 |
| US7153943B2 (en) * | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| US7270809B2 (en) * | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
| PL352223A1 (en) * | 1999-04-13 | 2003-08-11 | Kenneth S Warren Inst | Modulation of excitable tissue function by peripherally administered erythropoietin |
| WO2001083548A1 (en) * | 2000-04-28 | 2001-11-08 | Effector Cell Institute | Novel derivative of cell chemotactic factor |
| AU2002233230B2 (en) * | 2000-12-20 | 2007-02-01 | F. Hoffmann-La Roche Ag | Erythropoietin conjugates |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| PA8536201A1 (es) | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| RU2003125654A (ru) * | 2001-02-06 | 2005-03-10 | Мерк Патент ГмбХ (DE) | Модифицированный эритропоэтин (еро) с уменьшенной иммуногенностью |
| DE60232870D1 (de) * | 2001-04-04 | 2009-08-20 | Genodyssee | Neue polynukleotide und polypeptide des erythropoietingens |
| KR100467751B1 (ko) * | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
| US7300915B2 (en) * | 2002-06-05 | 2007-11-27 | The Regents Of The University Of California | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain |
| CA2491567A1 (en) | 2002-07-01 | 2004-01-08 | The Kenneth S. Warren Institute, Inc. | Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
| KR100478455B1 (ko) | 2002-08-19 | 2005-03-22 | 삼성전자주식회사 | 전자렌지 |
| ZA200505423B (en) | 2002-09-09 | 2008-08-27 | Warren Pharmaceuticals Inc | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| EP1578432A4 (en) * | 2002-10-03 | 2008-07-30 | Epimmune Inc | HLA BINDING PEPTIDES AND USES THEREOF |
| JP2004305006A (ja) * | 2003-04-01 | 2004-11-04 | Japan Science & Technology Agency | 人工調製肺サーファクタント |
| CN103230415B (zh) * | 2003-04-25 | 2016-05-04 | 匹兹堡大学联邦制高等教育 | 用于促进和增强神经修复和再生的肌肉来源的细胞（mdc） |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| CN1882355A (zh) | 2003-09-09 | 2006-12-20 | 沃伦药品公司 | 保持内源性促红细胞生成素组织保护活性的长效促红细胞生成素 |
| KR20070008519A (ko) | 2003-09-29 | 2007-01-17 | 워렌 파마슈티칼즈 인코포레이티드 | 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인 |
| US7842661B2 (en) | 2003-11-24 | 2010-11-30 | Novo Nordisk A/S | Glycopegylated erythropoietin formulations |
| US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
| WO2007010552A2 (en) | 2005-03-17 | 2007-01-25 | Serum Institute Of India Limited | N- terminal peg conjugate of erythropoietin |
| US9345745B2 (en) | 2005-04-29 | 2016-05-24 | Bo Wang | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides |
| WO2007052154A2 (en) | 2005-04-29 | 2007-05-10 | University Of Medicine And Dentistry Of New Jersey | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators |
| EP2377884A1 (en) | 2005-05-10 | 2011-10-19 | Neoloch Aps | Neuritogenic peptides |
| EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
| PT2371855E (pt) * | 2005-08-05 | 2015-11-03 | Araim Pharmaceuticals Inc | Péptidos protetores de tecidos e suas utilizações |
| ATE554186T1 (de) | 2007-11-29 | 2012-05-15 | Molecular Health Gmbh | Eph-b4 spezifische sirna zur reduktion von epo- induziertem tumorzellwachstum während anämiebehandlung in krebspatienten, gewebeschutz- erythropoietin-rezeptor (nepor) und verfahren zu seiner verwendung |
| SG10201604530SA (en) | 2008-01-22 | 2016-07-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| CA2725601A1 (en) * | 2008-04-28 | 2009-11-05 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
| WO2011022056A2 (en) | 2009-08-18 | 2011-02-24 | Medical College Of Georgia Research Institute, Inc. | PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF |
-
2006
- 2006-08-07 PT PT111631941T patent/PT2371855E/pt unknown
- 2006-08-07 ES ES12175366.9T patent/ES2653790T3/es active Active
- 2006-08-07 DK DK12175366.9T patent/DK2594279T3/en active
- 2006-08-07 IN IN2050CHN2014 patent/IN2014CN02050A/en unknown
- 2006-08-07 CA CA2982909A patent/CA2982909A1/en not_active Abandoned
- 2006-08-07 EP EP12175352.9A patent/EP2540309B1/en active Active
- 2006-08-07 KR KR1020187016750A patent/KR20180067735A/ko not_active Ceased
- 2006-08-07 SG SG10201805825SA patent/SG10201805825SA/en unknown
- 2006-08-07 KR KR1020177005579A patent/KR20170027868A/ko not_active Ceased
- 2006-08-07 MX MX2016004825A patent/MX364100B/es unknown
- 2006-08-07 UA UAA200802850A patent/UA100222C2/uk unknown
- 2006-08-07 PT PT121753529T patent/PT2540309T/pt unknown
- 2006-08-07 JP JP2008525285A patent/JP5274253B2/ja not_active Expired - Fee Related
- 2006-08-07 PL PL12175352T patent/PL2540309T3/pl unknown
- 2006-08-07 AU AU2006278264A patent/AU2006278264B2/en not_active Ceased
- 2006-08-07 KR KR1020197019568A patent/KR20190084136A/ko not_active Ceased
- 2006-08-07 PL PL11163194T patent/PL2371855T3/pl unknown
- 2006-08-07 NZ NZ565937A patent/NZ565937A/en not_active IP Right Cessation
- 2006-08-07 KR KR1020087005373A patent/KR101626153B1/ko not_active Expired - Fee Related
- 2006-08-07 LT LTEP12175352.9T patent/LT2540309T/lt unknown
- 2006-08-07 SG SG2014007868A patent/SG2014007868A/en unknown
- 2006-08-07 CA CA2618396A patent/CA2618396C/en not_active Expired - Fee Related
- 2006-08-07 SI SI200632230T patent/SI2594279T1/en unknown
- 2006-08-07 MX MX2014011168A patent/MX339613B/es unknown
- 2006-08-07 BR BRPI0614529A patent/BRPI0614529A8/pt not_active Application Discontinuation
- 2006-08-07 HU HUE12175352A patent/HUE035793T2/en unknown
- 2006-08-07 EP EP06801051A patent/EP1924276A4/en not_active Withdrawn
- 2006-08-07 CA CA3079319A patent/CA3079319A1/en not_active Abandoned
- 2006-08-07 EP EP12175366.9A patent/EP2594279B1/en active Active
- 2006-08-07 SI SI200632233T patent/SI2540309T1/en unknown
- 2006-08-07 LT LTEP12175366.9T patent/LT2594279T/lt unknown
- 2006-08-07 MX MX2008001509A patent/MX2008001509A/es active IP Right Grant
- 2006-08-07 ES ES12175352.9T patent/ES2653864T3/es active Active
- 2006-08-07 KR KR1020207016998A patent/KR20200072568A/ko not_active Ceased
- 2006-08-07 EP EP17202352.5A patent/EP3363451A1/en not_active Withdrawn
- 2006-08-07 DK DK11163194.1T patent/DK2371855T3/en active
- 2006-08-07 CN CN2006800348244A patent/CN101378772B/zh not_active Expired - Fee Related
- 2006-08-07 PT PT121753669T patent/PT2594279T/pt unknown
- 2006-08-07 HU HUE11163194A patent/HUE026444T2/en unknown
- 2006-08-07 WO PCT/US2006/031061 patent/WO2007019545A2/en not_active Ceased
- 2006-08-07 ES ES11163194.1T patent/ES2550055T3/es active Active
- 2006-08-07 KR KR1020137016015A patent/KR101713368B1/ko not_active Expired - Fee Related
- 2006-08-07 KR KR1020187030050A patent/KR20180116475A/ko not_active Ceased
- 2006-08-07 CN CN201310529242.5A patent/CN103724418B/zh not_active Expired - Fee Related
- 2006-08-07 SI SI200631979T patent/SI2371855T1/sl unknown
- 2006-08-07 HU HUE12175366A patent/HUE035655T2/en unknown
- 2006-08-07 DK DK12175352.9T patent/DK2540309T3/en active
- 2006-08-07 EP EP11163194.1A patent/EP2371855B1/en active Active
- 2006-08-07 US US11/997,898 patent/US8071554B2/en not_active Expired - Fee Related
- 2006-08-07 PL PL12175366T patent/PL2594279T3/pl unknown
- 2006-08-07 EA EA200800536A patent/EA015672B1/ru not_active IP Right Cessation
-
2008
- 2008-02-05 IL IL189287A patent/IL189287A/en active IP Right Grant
- 2008-03-03 NO NO20081112A patent/NO20081112L/no not_active Application Discontinuation
-
2011
- 2011-03-11 ZA ZA2011/01890A patent/ZA201101890B/en unknown
- 2011-10-20 US US13/278,131 patent/US8716245B2/en not_active Expired - Fee Related
-
2012
- 2012-04-16 US US13/448,345 patent/US8673861B2/en not_active Expired - Fee Related
-
2013
- 2013-02-15 JP JP2013027479A patent/JP5918155B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-08 US US14/248,030 patent/US9340598B2/en not_active Expired - Fee Related
-
2015
- 2015-02-04 JP JP2015020020A patent/JP6158235B2/ja not_active Expired - Fee Related
- 2015-02-10 US US14/618,873 patent/US20150152156A1/en not_active Abandoned
- 2015-06-29 IL IL239695A patent/IL239695A0/en active IP Right Grant
-
2016
- 2016-05-05 US US15/147,848 patent/US10100096B2/en not_active Expired - Fee Related
- 2016-06-08 JP JP2016114010A patent/JP6491621B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-03 JP JP2018071318A patent/JP2018134084A/ja active Pending
- 2018-08-23 IL IL261346A patent/IL261346A/en unknown
- 2018-09-25 US US16/141,724 patent/US20190016769A1/en not_active Abandoned
-
2020
- 2020-01-30 JP JP2020013151A patent/JP2020078317A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018134084A5 (enExample) | ||
| JP2016196480A5 (enExample) | ||
| Fulton et al. | Retinal degenerative and hypoxic ischemic disease | |
| AU2010251788B2 (en) | Novel agents for ameliorating motor disorder | |
| Li et al. | Systemic hypothermia induced within 10 hours after birth improved neurological outcome in newborns with hypoxic-ischemic encephalopathy | |
| WO2019029273A1 (zh) | 4-氧-烷基化特特拉姆酸类化合物及其制备方法与应用 | |
| WO2019029274A1 (zh) | 4-氧-烷基化特特拉姆酸类化合物及其制备方法 | |
| JP2016508036A5 (enExample) | ||
| Bugrov et al. | Influence of If-current blockade on rat heart contractility with a model of myocardial infarction | |
| US20090163432A1 (en) | Therapeutic Agent for Corneal Diseases | |
| Ermatov et al. | Results of life quality assessment in rehabilitation treatment of children with traumatic brain injury | |
| Jolly | Treatment of traumatic brain injury in Morepork owls: a review of diagnostic and treatment options | |
| Fotbolcu et al. | Reversible myocardial stunning due to carbon monoxide exposure | |
| RU2462182C2 (ru) | Способ ранней диагностики хронических нарушений мозгового кровообращения, обусловленных артериальной гипотензией | |
| Kestane | Diabetic Retinopathy and Stem Cell Therapy | |
| Li et al. | The effect of mild hypothermia on Nogo-A and neurological function in the brain after cardiopulmonary resuscitation in rats | |
| De Pont et al. | Recovery from near drowning and postanoxic status epilepticus with controlled hypothermia | |
| Arias-Carrión et al. | Cell transplantation: a future therapy for narcolepsy? | |
| Renziak et al. | Features of daily patterns of blood flow parameters in the internal carotid arteries in primary open-angle glaucoma | |
| Bibhu et al. | Application of cardioplegic solution in clinical practice | |
| Balykova et al. | ROHHAD syndrome: clinical case and literature review | |
| Andrews et al. | The Effects of Stem Cells Plus Lithium on the Recovery of Spinal Cord Injury | |
| Yi-qing et al. | Analysis of genetic and clinical characteristics of Charcot-Marie-Tooth disease patients caused by ARSs gene variation | |
| US20250064802A1 (en) | Methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases | |
| Fuller et al. | Proceedings of the 249th Otago Medical School Research Society Meeting-Research Staff Speaker Awards; 24 Jul 2019 |